Education
About Us
Working with TipRanks
Follow Us
Anbio Biotechnology Class A (NNNN)
NASDAQ:NNNN
NNNN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.18 - $55.65
Previous CloseN/A
VolumeN/A
Average Volume (3M)168.30K
Market Cap
$6.34B
Enterprise ValueN/A
Total Cash (Recent Filing)$11.76M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)735.1
Beta1.50
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.06
Shares Outstanding43,891,200
10 Day Avg. Volume118,033
30 Day Avg. Volume168,301
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
NNNN FAQ
What was Anbio Biotechnology Class A’s price range in the past 12 months?
Anbio Biotechnology Class A lowest stock price was $5.18 and its highest was $55.65 in the past 12 months.
What is Anbio Biotechnology Class A’s market cap?
Anbio Biotechnology Class A’s market cap is $6.34B.
When is Anbio Biotechnology Class A’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Anbio Biotechnology Class A’s earnings last quarter?
Currently, no data Available
Is Anbio Biotechnology Class A overvalued?
According to Wall Street analysts Anbio Biotechnology Class A’s price is currently Overvalued.
Does Anbio Biotechnology Class A pay dividends?
Anbio Biotechnology Class A does not currently pay dividends.
What is Anbio Biotechnology Class A’s EPS estimate?
Anbio Biotechnology Class A’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Anbio Biotechnology Class A have?
Anbio Biotechnology Class A has 43,891,200 shares outstanding.
What happened to Anbio Biotechnology Class A’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Anbio Biotechnology Class A?
Currently, no hedge funds are holding shares in NNNN
Anbio Biotechnology Class A Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
15.00%
Trailing 12-Months
Asset Growth
12.18%
Trailing 12-Months
Company Description
Anbio Biotechnology Class A
Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, Africa, and internationally. It offers SARS-CoV-2 antigen rapid and SARS-CoV-2/influenza A/B antigen rapid tests; and lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, chemiluminescence immunoassay, and reverse-transcription polymerase chain reaction products. It serves over-the-counter, point-of-care testing, and laboratory markets. The company was incorporated in 2021 and is based in Frankfurt am Main, Germany.
Anbio Biotechnology Class A (NNNN) Earnings & Revenues
Currently, no data available
Please return soon. This page is being updated.
Technical Analysis
Merit Medical Systems
―
Repligen
―
Teleflex
―
Stevanato Group
―
Bausch + Lomb Corporation
―
Ownership Overview
―
Insiders
0.04%
Mutual Funds
― Other Institutional Investors
99.96% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---